Naproxen immediate-release - Oxford Pharmascience

Drug Profile

Naproxen immediate-release - Oxford Pharmascience

Alternative Names: Gastric-safe naproxen; Immediate release naproxen - Oxford Pharmasciences; OXP 005; OXPzero™ naproxen

Latest Information Update: 08 Jul 2015

Price : $50

At a glance

  • Originator Oxford Pharmascience
  • Class Antipyretics; Antirheumatics; Naphthaleneacetic acids; Nonsteroidal anti-inflammatories; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Musculoskeletal pain

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 13 Jun 2015 Interim pharmacokinetics data from a phase I trial in Musculoskeletal pain released by Oxford Pharmascience
  • 01 Jun 2015 Oxford Pharmascience completes a phase I trial for Musculoskeletal pain in United Kingdom (NCT02408978)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top